



ClearGuard™ HD

Antimicrobial Barrier Caps for Hemodialysis Catheters

Clinically proven to reduce the rate of CLABSIs in hemodialysis catheter patients

icumedical
human connections

Reduce hemodialysis catheter infections with clinically proven technology

Catheter infections are frequent, costly, and deadly

- > Catheters cause 70% of vascular access-related BSIs and central venous catheters (CVCs) are used in only 19% of all dialysis procedures in the United States¹
- > Central line-associated bloodstream infections (CLABSIs) are a leading cause of hospitalizations and the second leading cause of death in hemodialysis patients^{1,2}
- > CLABSIs are very expensive, with an estimated increase in healthcare costs of approximately \$27,232–\$68,983, with an average of \$48,108 per infection³




Reduce hemodialysis catheter infections by up to 63%⁴

The ClearGuard HD antimicrobial barrier cap is the first and only device for sale designed to kill infection-causing bacteria inside a hemodialysis catheter hub.* ClearGuard HD features a rod that extends into the hemodialysis catheter hub. The rod and cap threads are coated with chlorhexidine, a well-known broad-spectrum antimicrobial agent.

Antimicrobial agent remains in desired region due to the existing clamps

The ClearGuard HD rod and threads are coated with chlorhexidine, a broad-spectrum antimicrobial agent



- > When the ClearGuard HD cap is inserted into a liquid-filled catheter, chlorhexidine elutes from the rod into the catheter lock solution
- > The chlorhexidine coating dissolves to kill microorganisms on the inside and outside of the catheter hub
- > The existing catheter clamp holds the antimicrobial agent inside the catheter hub between treatments
- > ClearGuard HD caps are used in place of a standard cap or connector
- > Designed to meet your needs, ClearGuard HD caps can be used with heparin, citrate and saline solutions.

*Designed to kill microorganisms, not intended to be used for treatment of existing infections.


Curios is a registered trademark of 3M Company.

ClearGuard HD antimicrobial barrier caps have been clinically proven to reduce CLABSIs in hemodialysis catheter patients^{4,5}

Multiple large, prospective, cluster-randomized multicenter open-label trials demonstrated a significant reduction in the rate of positive blood cultures (PBCs) and CLABSIs using ClearGuard HD caps versus control groups.



Cluster-Randomized Trial of Devices to Prevent Catheter-Related Bloodstream Infections



ClearGuard HD Caps vs. Tego™ + Curos™


Brunelli, SM et al. Cluster-randomized trial of devices to prevent catheter-related bloodstream infection. J Am Soc Nephrol 2018 Apr; 29(4):1336-1343.

- > 13-month prospective, cluster-randomized multicenter open-label trial
- > 1,671 patients (826 treatment, 845 control) accruing ~183,000 CVC days
- > 40 centers across the US
- > Primary endpoint was PBC rate as an indicator of BSI rate

Results: Use of the ClearGuard HD caps for 13 months was associated with a 63% lower BSI rate vs. use of Tego + Curos. When considering the de novo subgroup (new CVCs), use of ClearGuard HD caps was associated with a 72% lower BSI rate.



Dialysis Catheter-Related Bloodstream Infections: A Cluster-Randomized Trial of the ClearGuard HD Antimicrobial Barrier Cap



ClearGuard HD Caps vs. Standard Dialysis Caps



Hymes, JL et al. Dialysis catheter-related bloodstream infections: A cluster-randomized trial of the ClearGuard HD antimicrobial barrier cap. Am J Kidney Dis. 2017; 69(2):220-227.

- > 12-month prospective, cluster-randomized, multicenter, open-label comparative effectiveness trial in hemodialysis patients with central venous catheters
- > 2,470 patients (1,245 treatment, 1,225 control) accruing ~350,000 CVC days
- > 40 centers across the US
- > Primary endpoint was PBC rate as an indicator of BSI rate

Results: Use of the ClearGuard HD caps for 12 months was associated with a 56% lower BSI rate vs. use of standard caps. When considering sustained use (defined as 6 months of the study), the intervention vs. control was associated with a 69% lower BSI rate.

ClearGuard HD antimicrobial barrier caps used by leading hospitals and clinics

For years, dialysis staff at hospitals and clinics have focused on educational initiatives to reduce bloodstream infections in hemodialysis patients with limited impact. ClearGuard HD caps succeed in reducing infections by killing bacteria where bloodstream infections start-inside the hemodialysis catheter hub. With over 950 hospitals and over 4,600 outpatient dialysis clinics as customers, ClearGuard HD caps are becoming an increasingly important part of hemodialysis infection control best practices.



Recommended in Infusion Therapy Standards of Practice 9th edition: 2024

INS SOP, 27. Vascular Access and Hemodialysis, Section C3, For patients receiving hemodialysis through a CVAD, consider the use of an antimicrobial barrier cap as a strategy to reduce bloodstream infections. (Practice Recommendations)

INS SOP, 47. Vascular Access Device-Related Infection, Section J, For patients receiving outpatient dialysis through a central venous catheter, consider the use of an antimicrobial barrier cap as a strategy to reduce bloodstream infection. (Practice Recommendations)



Recommended in NKF's KDOQI Clinical Practice Guideline for Vascular Access: 2019⁶

21.3 KDOQI considers it reasonable to use an antimicrobial barrier cap to help reduce CRBSI in high-risk patients or facilities; the choice of connector should be based on clinician's discretion and best clinical judgment. (Expert Opinion)



Special Report published by Global Business Media exclusively features ClearGuard HD

Titled: *Reducing Catheter Related Bloodstream Infections in Hemodialysis Patients*



Recommended in the UK's NICE National Guidance for hemodialysis catheter-related bloodstream infections: 2021^{**}

<https://www.nice.org.uk/guidance/mtg62/>

Product Ordering information

Product Code	Case Quantity	Product Description
CGHD-100	100	ClearGuard™ HD Caps (1 Red, 1 Blue)



¹ Nguyen OB, Shugart A, Lines C, Shah AB, Edwards J, Pollock D, Sievert D, Patel PR. National healthcare safety network (NHSN) dialysis event surveillance report for 2014. Clin J Am Soc Nephrol 12(7), 1139-1146, 2017.

² United States Renal Data System. 2018 USRDS annual report: Epidemiology of kidney disease in the United States. National Institutes of Health, Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2018.

³ Results. Content last reviewed November 2017. Agency for Healthcare Research and Quality, Rockville, MD. <https://www.ahrq.gov/hai/pfp/haccost2017-results.html>

⁴ Brunelli, SM et al. Cluster-randomized trial of devices to prevent catheter-related bloodstream infection. J Am Soc Nephrol. 2018 Apr;29(4):1336-1343.

⁵ Hymes, JL et al. Dialysis catheter-related bloodstream infections: a cluster-randomized trial of the ClearGuard HD antimicrobial barrier cap. Am J Kidney Dis. 2017 Feb;69(2):220-227.

⁶ Lok CE, Huber TS, Lee T, et al; KDOQI Vascular Access Guideline Work Group. KDOQI clinical practice guideline for vascular access: 2019 update. Am J Kidney Dis. 2020;75(4)(suppl 3):S1-S164.

Contact us today to find out how ClearGuard HD can play a large role in your infection control practices. Visit www.icumed.com or call 866.488.6088

